Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say

New data from a trial of an investigational mRNA vaccine shows that it reduced the risk of recurrence of the serious skin cancer melanoma when combined with immunotherapy, according to drugmakers Moderna and Merck. In a trial of 157 people who had had surgery to treat melanoma, 78.6% of those who…#merck #keytruda #kyleholen #mrna4157v940
Source: Reuters: Health - Category: Consumer Health News Source Type: news